IMMUNESENSE Trademark

Trademark Overview

On Tuesday, July 21, 2020, a trademark application was filed for IMMUNESENSE with the United States Patent and Trademark Office. The USPTO has given the IMMUNESENSE trademark a serial number of 90065411. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 25, 2023. This trademark is owned by Adaptive Biotechnologies Corp.. The IMMUNESENSE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical laboratory services provided to generate immune cell receptor data for research and the development of diagnostic tests; scientific laboratory services provided to generate immune cell receptor data for research and the development of diagnostic tests
immunesense

General Information

Serial Number90065411
Word MarkIMMUNESENSE
Filing DateTuesday, July 21, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 25, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 28, 2021

Trademark Statements

Pseudo MarkIMMUNE SENSE
Goods and ServicesMedical laboratory services provided to generate immune cell receptor data for research and the development of diagnostic tests; scientific laboratory services provided to generate immune cell receptor data for research and the development of diagnostic tests

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, August 18, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAdaptive Biotechnologies Corp.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeattle, WA 98102
Party NameAdaptive Biotechnologies Corp.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98102

Trademark Events

Event DateEvent Description
Monday, September 25, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, September 25, 2023ABANDONMENT - NO USE STATEMENT FILED
Friday, February 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 22, 2023SOU EXTENSION 2 GRANTED
Wednesday, February 22, 2023SOU EXTENSION 2 FILED
Wednesday, February 22, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 24, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 22, 2022SOU EXTENSION 1 GRANTED
Monday, August 22, 2022SOU EXTENSION 1 FILED
Monday, August 22, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, February 22, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 28, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 28, 2021PUBLISHED FOR OPPOSITION
Wednesday, December 8, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 23, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 19, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, November 19, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, November 19, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, May 21, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 21, 2021NON-FINAL ACTION E-MAILED
Friday, May 21, 2021NON-FINAL ACTION WRITTEN
Wednesday, May 5, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 4, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 4, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, November 5, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, November 5, 2020NON-FINAL ACTION E-MAILED
Thursday, November 5, 2020NON-FINAL ACTION WRITTEN
Wednesday, November 4, 2020ASSIGNED TO EXAMINER
Tuesday, August 18, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, July 24, 2020NEW APPLICATION ENTERED

Related Keywords

immunesense research data development diagnostic tests receptor cell laboratory services provided